Clinical Trial

Monthly Alternating NALIRIFOX and GnP in the First-Line Setting for Metastatic Pancreatic Ductal Adenocarcinoma

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
A prospective, interventional, single-center, single-arm, open-label, phase II study for patients with metastatic pancreatic cancer. The intervention consists of monthly alternating standard chemotherapy regimens-NALIRIFOX and GnP. The hypothesis is that induction therapy with alternating NALIRIFOX and GnP has better efficacy compared to historical observation.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-09-02; most recent amendment 2026-03-16.
Trial Details
NCT Number NCT07163273
Lead Sponsor Northwell Health
Conditions Pancreatic Ductal Adenocarcinoma
Enrollment 41 participants
Start Date 2025-06-20
Primary Completion 2027-06-20 (estimated)
Study Completion 2027-06-20 (estimated)
Updated on ClinicalTrials.gov 2026-03-18